Canadian Cancer Society logo

Non-Hodgkin lymphoma

You are here: 

Hepatosplenic T-cell lymphoma

Hepatosplenic T-cell lymphoma (HSTL or HSTCL) is a rare T-cell non-Hodgkin lymphoma (NHL). It tends to occur more often in teenage boys and young adult men. It sometimes develops in people with a suppressed immune system, such as after an organ transplant. It may also be called hepatosplenic gamma delta T-cell lymphoma.

HSTL is often difficult to diagnose. HSTL usually involves the liver or spleen. As a result, people with HSTL often have an enlarged liver (hepatomegaly), an enlarged spleen (splenomegaly) or both (hepatosplenomegaly). The bone marrow is also commonly involved. HSTL is associated with symptoms like fatigue, B symptoms, anemia and abnormally low platelet counts (thrombocytopenia). Lymph nodes are not usually enlarged.

HSTL is a very fast-growing (aggressive) lymphoma. The prognosis for people with this type of lymphoma is often poor.


There is no standard treatment for HSTL.


Most often, people with HSTL are treated with combination chemotherapy. CHOP or CHOP-like therapies are used.

  • CHOP – cyclophosphamide (Cytoxan, Procytox), doxorubicin (Adriamycin), vincristine (Oncovin) and prednisone (Deltasone)

Although most people respond to chemotherapy at first, many will relapse.

Stem cell transplant

A stem cell transplant (SCT) may be an option for some people with HSTL.

For more detailed information on specific drugs, go to sources of drug information.


Dr Christine Friedenreich Preventing cancer through physical activity

Read more

Clinical trial discovery improves quality of life

Illustration of test tubes

A clinical trial led by the Society’s NCIC Clinical Trials group found that men with prostate cancer who are treated with intermittent courses of hormone therapy live as long as those receiving continuous therapy.

Learn more